Huadong Medicine
Huadong Medicine
Huadong Medicine is a comprehensive pharmaceuticals company.
Huadong Medicine, founded in March 1993 and headquartered in Hangzhou, is a comprehensive manufacturer and distributor of various types of antibiotics, proprietary Chinese medicines, and synthetic drugs. The founder is Lu Liang. Listed on the Shenzhen Stock Exchange on January 27, 2020, the company's major shareholders are China Grand Enterprises and Hangzhou Huadong Medicine. The direct and indirect competitors of Huadong Medicine include Hengrui Medicine, Humanwell Healthcare, Kelun Pharmaceutical.
- All
- News
- Analysis
- Research
Briefing Jan 10, 2022 11:16 AM
· Healthcare
Lanjing microorganism completed a total of RMB 1.5 billion of Series B financing and accelerated the implementation of the "T-type" development strategy
In depth
Briefing Jan 06, 2022 03:39 PM
· Healthcare
Xinmai medical announced strategic cooperation with rainbow medical, a famous medical device incubator in Israel
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Real Estate, Industrials, FinancialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Real Estate, Industrials, FinancialsLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Oct 29, 2021 11:38 AM
Financial Associated Press, October 29 - a carbon monoxide poisoning accident occurred in an ironmaking plant in Xingtai, Hebei Province. Three people died after ineffective rescue.
In depth
Healthcare
Dada group's revenue rose nearly 30% in the third quarter, and JD's "hour purchase" cont
Looking forward to the fourth quarter of 2021, dada Group expects its total revenue to be between 2 billion yuan and 2.1 billion yuan. On the premise that the last kilometer of dada express delivery service is consistent with the comparable basis, the total revenue in the fourth quarter of 2021 will achieve a year-on-year increase of 88% to 97%.
Nov 24, 2021 11:42 AM
Insight
Briefing Jul 06, 2021 10:41 AM
· Healthcare
Yimei concept stocks all weakened, Aoyuan Meigu closed down
See more
Related Companies
EqualOcean Analysis
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO
- Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
- More Room for the Medical Device Market to Grow in China
- Modern Chinese Medicine Maker Tasly Pharmaceutical: An Old Stock in a New Package?
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.